Fierce Pharma August 28, 2024
Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs.
For $20 million upfront, Novartis has obtained exclusive global rights to use Lindy’s Microglassifiction suspension technology to design high-concentration, self-administered drugs against multiple biologic targets, Lindy said Wednesday.
If everything goes according to plan, Lindy may receive up to $934 million in milestone payments, plus tiered single-digit royalties on potential sales.
The deal “marks a significant milestone as we take Lindy’s formulation technology into the clinic for the first time,” Lindy’s founder and CEO, Deborah Bitterfield, Ph.D., said in a statement Wednesday.
Founded in 2016, Lindy is headquartered in Morrisville, North Carolina. Its core Microglassifiction technology aims to...
Today's Sponsors
Today's Sponsor